Da: Lucky's Textbooks, Dallas, TX, U.S.A.
EUR 51,69
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
EUR 56,13
Quantità: 10 disponibili
Aggiungi al carrelloPF. Condizione: New.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 58,49
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
Condizione: New. pp. 252.
EUR 76,49
Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 252 pages. 9.02x5.98x0.57 inches. In Stock.
EUR 48,37
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
EUR 53,49
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The scientific work of Walther Birkmayer is grounded on his ability to turn what was often a mass of clinical details into the basis for a hypothesis for a new therapeutic approach toward solving the problems of a patient's illness. Birkmayer first became known when, during the Second World War, he built up a clinic for brain injuries in Vienna, in which over 3000 patients were treated. The study of changes in the autonomic functions of the nervous system in these patients as well as the problems of rehabilitation were published in a monograph, 'Hirn verletzungen'. Consequently, this was his major scientific interest during the post-war years. His book, 'Klinik und Therapie der vegetativen Funktionsstorungen' published with W. Winkler, brought Birkmayer recognition in the German-speaking world. In 1954 he took over the Neurological Department of the Geriatric Hospital of Vienna in Lainz, where he remained until his retirement in 1975. International acclaim followed his breakthrough with the clinical application of L-DOPA in Parkinson's disease. Birkmayer, as a strong adherent to the scientific interpretation of neurological and psychiatric disease, has encouraged multidisciplinary research. This is reflected in his establishment of the former Ludwig Boltzmann Institute of Neurochemistry, in which pharmacological, biochemical and histopathological research into neuropsychiatric diseases was performed under one roof. Further to his initial work on L-DOPA, Birkmayer has been in the forefront of supplementary parkinsonian therapy using enzyme inhibitors: benserazide in 1967, unselective monoamine oxidase inhibitors in 1962 and deprenyl in 1975.
Lingua: Inglese
Editore: Springer Vienna, Springer Dez 2011, 2011
ISBN 10: 370918584X ISBN 13: 9783709185841
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 53,49
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The scientific work of Walther Birkmayer is grounded on his ability to turn what was often a mass of clinical details into the basis for a hypothesis for a new therapeutic approach toward solving the problems of a patient's illness. Birkmayer first became known when, during the Second World War, he built up a clinic for brain injuries in Vienna, in which over 3000 patients were treated. The study of changes in the autonomic functions of the nervous system in these patients as well as the problems of rehabilitation were published in a monograph, 'Hirn verletzungen'. Consequently, this was his major scientific interest during the post-war years. His book, 'Klinik und Therapie der vegetativen Funktionsstorungen' published with W. Winkler, brought Birkmayer recognition in the German-speaking world. In 1954 he took over the Neurological Department of the Geriatric Hospital of Vienna in Lainz, where he remained until his retirement in 1975. International acclaim followed his breakthrough with the clinical application of L-DOPA in Parkinson's disease. Birkmayer, as a strong adherent to the scientific interpretation of neurological and psychiatric disease, has encouraged multidisciplinary research. This is reflected in his establishment of the former Ludwig Boltzmann Institute of Neurochemistry, in which pharmacological, biochemical and histopathological research into neuropsychiatric diseases was performed under one roof. Further to his initial work on L-DOPA, Birkmayer has been in the forefront of supplementary parkinsonian therapy using enzyme inhibitors: benserazide in 1967, unselective monoamine oxidase inhibitors in 1962 and deprenyl in 1975. 252 pp. Englisch.
Da: Majestic Books, Hounslow, Regno Unito
EUR 71,83
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand pp. 252 31 Figures, 23:B&W 6 x 9 in or 229 x 152 mm Perfect Bound on White w/Gloss Lam.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 74,34
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND pp. 252.
Lingua: Inglese
Editore: Springer Vienna, Springer Vienna Dez 2011, 2011
ISBN 10: 370918584X ISBN 13: 9783709185841
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 53,49
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The scientific work of Walther Birkmayer is grounded on his ability to turn what was often a mass of clinical details into the basis for a hypothesis for a new therapeutic approach toward solving the problems of a patient's illness. Birkmayer first became known when, during the Second World War, he built up a clinic for brain injuries in Vienna, in which over 3000 patients were treated. The study of changes in the autonomic functions of the nervous system in these patients as well as the problems of rehabilitation were published in a monograph, 'Hirn verletzungen'. Consequently, this was his major scientific interest during the post-war years. His book, 'Klinik und Therapie der vegetativen Funktionsstorungen' published with W. Winkler, brought Birkmayer recognition in the German-speaking world. In 1954 he took over the Neurological Department of the Geriatric Hospital of Vienna in Lainz, where he remained until his retirement in 1975. International acclaim followed his breakthrough with the clinical application of L-DOPA in Parkinson's disease. Birkmayer, as a strong adherent to the scientific interpretation of neurological and psychiatric disease, has encouraged multidisciplinary research. This is reflected in his establishment of the former Ludwig Boltzmann Institute of Neurochemistry, in which pharmacological, biochemical and histopathological research into neuropsychiatric diseases was performed under one roof. Further to his initial work on L-DOPA, Birkmayer has been in the forefront of supplementary parkinsonian therapy using enzyme inhibitors: benserazide in 1967, unselective monoamine oxidase inhibitors in 1962 and deprenyl in 1975.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 252 pp. Englisch.
Da: preigu, Osnabrück, Germania
EUR 50,25
Quantità: 5 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Current Topics in Extrapyramidal Disorders | A. Carlsson (u. a.) | Taschenbuch | x | Englisch | 2011 | Springer | EAN 9783709185841 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.